ArticleCancer immunology, immunotherapy : CII2019

Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.

Aldo Bonaventura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.